Table 2 Percentage mean cytotoxicities of DNA-acting drugs and their combinations with Nar on human colorectal and breast cancer cells
Treatment with DNA-acting drugs and their combinations with Nar | Percentage mean cytotoxicity a | Fold increase in therapeutic efficacy | ||
|---|---|---|---|---|
SW837 | HTB132 | SW837 b | HTB132 c | |
5 FU (1 × 10−10 - 1 × 10−3 M) | 8 ± 1.0 | 54 ± 0.42 | ||
5 FU (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 50 ± 1.6 | 96 ± 0.44 | 6.25 | 1.7 |
CIP (1 × 10−10 - 1 × 10−3 M) | 3 ± 0.8 | 49 ± 0.5 | ||
CIP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 39 ± 2 | 80 ± 0.6 | 13 | 1.63 |
CAP (1 × 10−10 - 1 × 10−3 M) | 9 ± 2 | 40 ± 2 | ||
CAP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 27 ± 1.0 | 83 ± 1.5 | 3 | 2.1 |
CPT (1 × 10−10 - 1 × 10−3 M) | 8 ± 1.1 | 60 ± 2.2 | ||
CPT (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 50 ± 2.6 | 95 ± 0.3 | 6.25 | 1.58 |
DOX (1 × 10−10 - 1 × 10−3 M) | 6 ± 1.3 | 54 ± 1.3 | ||
DOX (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 41 ± 3 | 84 ± 0.6 | 6.83 | 1.56 |
CPA (1 × 10−11 - 1 × 10−4 M) | 15 ± 2.6 | 44 ± 0.8 | ||
CPA (1 × 10-11 - 1 × 10-4 M) + Nar (0.5 mM) | 47 ± 1.1 | 88 ± 1 | 3.13 | 2 |
ETP (1 × 10−10 - 1 × 10−3 M) | 10 ± 2 | 51 ± 1.6 | ||
ETP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) | 57 ± 0.6 | 83 ± 0.93 | 5.7 | 1.63 |
ELP (1 × 10−11 - 1 × 10−4 M) | 23 ± 2.5 | 51 ± 1.6 | ||
ELP (1 × 10−11 - 1 × 10−4 M) + Nar (0.5 mM) | 70 ± 1.8 | 93 ± 0.6 | 3.04 | 1.82 |